The growing interest in cannabinoid-based therapies has led to an increasing demand for robust and reliable bioanalytical methods capable of supporting drug development programs. Beyond the quantification of parent compounds such as cannabidiol (CBD) and tetrahydrocannabinol (THC), there is a clear need to accurately monitor their main metabolites to better characterize pharmacokinetics, bioavailability, and overall drug exposure.
However, the simultaneous determination of multiple cannabinoids and their metabolites in biological matrices presents significant analytical challenges. In this context, Kymos has further expanded its expertise in cannabinoid bioanalysis through the development and validation of a sensitive and robust LC-MS/MS method for the simultaneous quantification of six key analytes, including CBD, THC, and their main metabolites in human plasma.
Analytical Challenges in Cannabinoid Bioanalysis
Cannabinoid bioanalysis is inherently complex due to several factors. These compounds are typically present at low concentrations, requiring highly sensitive analytical techniques. In addition, the structural similarity between parent compounds and their metabolites demands high selectivity to ensure accurate quantification.
Another key challenge lies in the need to cover a wide dynamic range of concentrations within a single method, particularly when both parent compounds and metabolites are included. Furthermore, biological matrices such as human plasma introduce potential interferences, making efficient sample preparation essential.
Finally, regulatory expectations have evolved, with guidelines such as ICH M10 establishing clear requirements for bioanalytical method validation, reinforcing the need for robust, reproducible, and compliant methodologies.
Method Overview
Target Analytes and Calibration Ranges
The developed method enables the simultaneous quantification of six analytes, including both parent compounds and their primary metabolites:
- CBD: 0.5–100 ng/mL
- 7-OH-CBD: 0.5–50 ng/mL
- 7-COOH-CBD: 0.5–500 ng/mL
- THC: 0.5–100 ng/mL
- 11-OH-THC: 0.5–50 ng/mL
- 11-COOH-THC: 0.5–500 ng/mL
This wide calibration range allows the method to cover concentrations typically observed in clinical studies, supporting comprehensive pharmacokinetic evaluations.
Sample Preparation Strategy
Sample preparation is based on 200 µL of human plasma using K₂EDTA as anticoagulant. A protein precipitation step with acetonitrile is applied, followed by filtration using Phree™ Phospholipid Removal 96-well plates.
This approach ensures efficient removal of phospholipids and other matrix components, improving method robustness and minimizing matrix effects, while also being suitable for high-throughput analysis.
Instrumental Analysis
The quantification of all analytes is performed using LC-MS/MS, enabling high sensitivity and selectivity. The method is designed to ensure reliable detection across all compounds within a single analytical run, supporting efficient multi-analyte analysis.
The system is based on a Triple Quad 6500+ mass spectrometer (Sciex), equipped with a TurboIonSpray ion source, providing the required sensitivity and robustness for the quantification of cannabinoids and their metabolites across a wide concentration range.
Method Validation under ICH M10
The method was fully validated under Good Laboratory Practice (GLP) in accordance with the ICH M10 guideline. Validation confirmed that the method is selective, linear, and compliant with bioanalytical requirements for precision, accuracy, and matrix effects. Stability, carryover, and high-throughput suitability were also demonstrated, supporting reliable analysis in regulated studies. The method achieves a lower limit of quantification (LLOQ) of 0.5 ng/mL for all analytes.
Key Strengths of the Method
- Simultaneous quantification of six cannabinoids and metabolites within a single method
- Broad calibration ranges covering both parent compounds and metabolites
- High sensitivity, with an LLOQ of 0.5 ng/mL
- Efficient and robust sample preparation
- Fully validated under GLP in compliance with ICH M10
Applications in Drug Development
This method is well suited to support a wide range of studies involving cannabinoid-based compounds, including:
- Pharmacokinetic studies
- Clinical trials (Phase I–IV)
- Bioavailability and bioequivalence studies
- Drug-drug interaction studies
Its ability to simultaneously quantify multiple analytes makes it particularly valuable for comprehensive exposure assessment and metabolite profiling in clinical settings.
Conclusion
Reliable cannabinoid bioanalysis requires a precise balance of high sensitivity and rigorous selectivity. By addressing these challenges directly, this validated six-analyte LC-MS/MS method offers a GLP-compliant solution for simultaneous metabolite profiling in human plasma.
The ability to track both parent compounds and their primary metabolites in a single run streamlines clinical workflows and ensures the data integrity required for modern drug development. This expanded capability provides the robust bioanalytical support necessary in cannabinoid pharmacokinetics and regulatory submission.
For more information on how these validated methods can support your clinical programs or to discuss a customized bioanalytical strategy, please contact our technical team at https://kymos.com/contact
